Literature DB >> 21949571

Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.

Vijay Sharma1, John H McNeill.   

Abstract

Diabetic cardiomyopathy is a disease process in which diabetes produces a direct and continuous myocardial insult even in the absence of ischemic, hypertensive or valvular disease. The β-blocking agents bisoprolol, carvedilol and metoprolol have been shown in large-scale randomized controlled trials to reduce heart failure mortality. In this review, we summarize the results of our studies investigating the effects of β-blocking agents on cardiac function and metabolism in diabetic heart failure, and the complex inter-related mechanisms involved. Metoprolol inhibits fatty acid oxidation at the mitochondrial level but does not prevent lipotoxicity; its beneficial effects are more likely to be due to pro-survival effects of chronic treatment. These studies have expanded our understanding of the range of effects produced by β-adrenergic blockade and show how interconnected the signaling pathways of function and metabolism are in the heart. Although our initial hypothesis that inhibition of fatty acid oxidation would be a key mechanism of action was disproved, unexpected results led us to some intriguing regulatory mechanisms of cardiac metabolism. The first was upstream stimulatory factor-2-mediated repression of transcriptional master regulator PGC-1α, most likely occurring as a consequence of the improved function; it is unclear whether this effect is unique to β-blockers, although repression of carnitine palmitoyltransferase (CPT)-1 has not been reported with other drugs which improve function. The second was the identification of a range of covalent modifications which can regulate CPT-1 directly, mediated by a signalome at the level of the mitochondria. We also identified an important interaction between β-adrenergic signaling and caveolins, which may be a key mechanism of action of β-adrenergic blockade. Our experience with this labyrinthine signaling web illustrates that initial hypotheses and anticipated directions do not have to be right in order to open up meaningful directions or reveal new information.

Entities:  

Keywords:  Cardiac metabolism; Diabetes; Fatty acid oxidation; Heart failure; β-blockers

Year:  2011        PMID: 21949571      PMCID: PMC3176897          DOI: 10.4330/wjc.v3.i9.281

Source DB:  PubMed          Journal:  World J Cardiol


  160 in total

1.  Structure-function relationships of the liver and muscle isoforms of carnitine palmitoyltransferase I.

Authors:  V A Zammit; N T Price; F Fraser; V N Jackson
Journal:  Biochem Soc Trans       Date:  2001-05       Impact factor: 5.407

Review 2.  Modulation of protein kinase signaling by protein phosphatases and inhibitors.

Authors:  Zhong-Yin Zhang; Bo Zhou; Laiping Xie
Journal:  Pharmacol Ther       Date:  2002 Feb-Mar       Impact factor: 12.310

3.  Elements regulating cardiomyocyte expression of the human sarcomeric mitochondrial creatine kinase gene in transgenic mice.

Authors:  W Qin; Z Khuchua; S C Klein; A W Strauss
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

Review 4.  The effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelines?

Authors:  Tonje Amb Aksnes; Sverre Erik Kjeldsen; Giuseppe Mancia
Journal:  Am J Cardiovasc Drugs       Date:  2006       Impact factor: 3.571

5.  Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway.

Authors:  V O Rybin; X Xu; M P Lisanti; S F Steinberg
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

6.  Diabetes reduces right atrial beta-adrenergic signaling but not agonist stimulation of heart rate in swine.

Authors:  W C Stanley; J J Dore; J L Hall; C D Hamilton; R D Pizzurro; D A Roth
Journal:  Can J Physiol Pharmacol       Date:  2001-04       Impact factor: 2.273

7.  Nitric oxide (NO) induces nitration of protein kinase Cepsilon (PKCepsilon ), facilitating PKCepsilon translocation via enhanced PKCepsilon -RACK2 interactions: a novel mechanism of no-triggered activation of PKCepsilon.

Authors:  Zarema Balafanova; Roberto Bolli; Jun Zhang; Yuting Zheng; Jason M Pass; Aruni Bhatnagar; Xian-Liang Tang; Ouli Wang; Ernest Cardwell; Peipei Ping
Journal:  J Biol Chem       Date:  2002-02-11       Impact factor: 5.157

8.  Metoprolol represses PGC1alpha-mediated carnitine palmitoyltransferase-1B expression in the diabetic heart.

Authors:  Vijay Sharma; Pavan Dhillon; Hannah Parsons; Michael F Allard; John H McNeill
Journal:  Eur J Pharmacol       Date:  2009-02-20       Impact factor: 4.432

9.  Expression of novel isoforms of carnitine palmitoyltransferase I (CPT-1) generated by alternative splicing of the CPT-ibeta gene.

Authors:  G S Yu; Y C Lu; T Gulick
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

10.  Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide.

Authors:  A Zai; M A Rudd; A W Scribner; J Loscalzo
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

View more
  11 in total

Review 1.  Nutrient sensing and utilization: Getting to the heart of metabolic flexibility.

Authors:  Timothy M Griffin; Kenneth M Humphries; Michael Kinter; Hui-Ying Lim; Luke I Szweda
Journal:  Biochimie       Date:  2015-10-22       Impact factor: 4.079

2.  β1-Adrenergic receptor blockade extends the life span of Drosophila and long-lived mice.

Authors:  Stephen R Spindler; Patricia L Mote; Rui Li; Joseph M Dhahbi; Amy Yamakawa; James M Flegal; Daniel R Jeske; Rui Li; Alex L Lublin
Journal:  Age (Dordr)       Date:  2013-01-15

Review 3.  Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management.

Authors:  Joseph M Pappachan; George I Varughese; Rajagopalan Sriraman; Ganesan Arunagirinathan
Journal:  World J Diabetes       Date:  2013-10-15

Review 4.  Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart.

Authors:  Raphael M Singh; Tahreem Waqar; Frank C Howarth; Ernest Adeghate; Keshore Bidasee; Jaipaul Singh
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

5.  Sympathetic hyper-excitation in obesity and pulmonary hypertension: physiological relevance to the 'obesity paradox'.

Authors:  C Diong; P P Jones; H Tsuchimochi; E A Gray; G Hughes; T Inagaki; C T Bussey; Y Fujii; K Umetani; M Shirai; D O Schwenke
Journal:  Int J Obes (Lond)       Date:  2016-02-23       Impact factor: 5.095

6.  β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.

Authors:  Hisashi Nagai; Ichiro Kuwahira; Daryl O Schwenke; Hirotsugu Tsuchimochi; Akina Nara; Tadakatsu Inagaki; Sayoko Ogura; Yutaka Fujii; Keiji Umetani; Tatsuo Shimosawa; Ken-ichi Yoshida; James T Pearson; Koichi Uemura; Mikiyasu Shirai
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

Review 7.  Diabetic cardiomyopathy: where we are and where we are going.

Authors:  Wang-Soo Lee; Jaetaek Kim
Journal:  Korean J Intern Med       Date:  2017-04-18       Impact factor: 2.884

8.  Network Pharmacology-Based Strategy Reveals the Effects of Hedysarum multijugum Maxim.-Radix Salviae Compound on Oxidative Capacity and Cardiomyocyte Apoptosis in Rats with Diabetic Cardiomyopathy.

Authors:  Shiying Zhang; Zhiying Yuan; Huaying Wu; Weiqing Li; Liang Li; Huiyong Huang
Journal:  Biomed Res Int       Date:  2020-10-17       Impact factor: 3.411

Review 9.  Application of Animal Models in Diabetic Cardiomyopathy.

Authors:  Wang-Soo Lee; Jaetaek Kim
Journal:  Diabetes Metab J       Date:  2021-03-25       Impact factor: 5.376

10.  Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy.

Authors:  Aude Carillion; Sarah Feldman; Na Na; Matthieu Biais; Wassila Carpentier; Aurélie Birenbaum; Nicolas Cagnard; Xavier Loyer; Dominique Bonnefont-Rousselot; Stéphane Hatem; Bruno Riou; Julien Amour
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.